sTRAIL-iRGD is a promising therapeutic agent for gastric cancer treatment
Author:
Publisher
Springer Science and Business Media LLC
Subject
Multidisciplinary
Link
http://www.nature.com/articles/s41598-017-00688-6.pdf
Reference34 articles.
1. Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E. & Forman, D. Global cancer statistics. CA Cancer J Clin 61, 69–90 (2011).
2. Siegel, R., Ma, J., Zou, Z. & Jemal, A. Cancer statistics, 2014. CA: a cancer journal for clinicians. 64, 9–29 (2014).
3. Sha, H. et al. Tumor-penetrating peptide fused EGFR single-domain antibody enhances cancer drug penetration into 3D multicellular spheroids and facilitates effective gastric cancer therapy. Journal of controlled release: official journal of the Controlled Release Society 200, 188–200 (2015).
4. Refaat, A., Abd-Rabou, A. & Reda, A. TRAIL combinations: The new ‘trail’ for cancer therapy (Review). Oncology letters 7, 1327–1332 (2014).
5. Pitti, R. M., Marsters, S. A., Ruppert, S., Donahue, C. J., Moore, A. & Ashkenazi, A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. The Journal of biological chemistry. 271, 12687–12690 (1996).
Cited by 18 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Dual targeting of DR5 and VEGFR2 molecular pathways by multivalent fusion protein significantly suppresses tumor growth and angiogenesis;International Journal of Biological Macromolecules;2024-01
2. Cancer therapy with iRGD as a tumor-penetrating peptide;Bulletin du Cancer;2023-12
3. Recent advances in the tumor‐penetrating peptide internalizing RGD for cancer treatment and diagnosis;Drug Development Research;2023-04-05
4. DR5-Selective TRAIL Variant DR5-B Functionalized with Tumor-Penetrating iRGD Peptide for Enhanced Antitumor Activity against Glioblastoma;International Journal of Molecular Sciences;2022-10-21
5. A novel tumor-homing TRAIL variant eradicates tumor xenografts of refractory colorectal cancer cells in combination with tumor cell-targeted photodynamic therapy;Drug Delivery;2022-05-30
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3